Overview
Retatrutide is a next-generation triple receptor agonist, simultaneously engaging GLP-1, GIP, and glucagon receptors. This triple mechanism distinguishes it from earlier dual-agonist compounds and has positioned it as one of the most intensively studied peptides in current metabolic and endocrine research.
Nova Biolabs holds Retatrutide 10mg in UK domestic stock and dispatches with fast, discreet packaging.
Key Research Areas
Triple Receptor Pharmacology
Retatrutide's simultaneous engagement of GLP-1, GIP, and glucagon receptors provides a unique research tool for studying the combined effects of incretin and glucagon signalling.
Glucagon Receptor Research
The addition of glucagon receptor agonism — absent in Tirzepatide — makes Retatrutide particularly valuable for researchers studying hepatic glucose production and energy expenditure pathways.
Comparative Agonist Studies
Frequently used alongside GLP-1-only and dual agonists to isolate the contribution of each receptor pathway in metabolic signalling models.
Energy Homeostasis Research
The triple-receptor profile has generated significant research interest in its effects on energy expenditure, thermogenesis signalling, and adipose tissue metabolism.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 10mg per vial |
| Grade | Research Grade |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |
Frequently Asked Questions
Commonly Stacked With
Compounds researchers often study alongside this one, and why.
Both feature in Nova’s Premium Bundle — MOTS-c’s mitochondrial signalling research is a common pairing alongside triple-receptor agonist studies.
Paired in the Premium Bundle — NAD+’s role in cellular energy pathways is frequently studied alongside metabolic receptor agonists.
Both feature in Nova’s Elite Bundle — GHRH-analogue research is commonly combined with metabolic receptor studies for broader endocrine-axis coverage.